<i>DPYD</i> c.1905 + 1G&gt;A Promotes Fluoropyrimidine-Induced Anemia, a Prognostic Factor in Disease-Free Survival, in Colorectal Cancer.

Deligonul A., Aksoy S., Tezcan G., Tunca B., Kanat O., Cubukcu E., ...More

Genetic testing and molecular biomarkers, vol.25, no.4, pp.276-283, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1089/gtmb.2020.0285
  • Journal Name: Genetic testing and molecular biomarkers
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.276-283
  • Keywords: DPYD c.1905+1G > A, fluoropyrimidine, anemia, colorectal cancer
  • Bursa Uludag University Affiliated: Yes


Background and Aim: In 10-30% of colorectal cancer (CRC) patients, toxic reactions occur after fluoropyrimidine-based chemotherapy. A dihydropyridine dehydrogenase (DPYD) gene variant, c.1905 + 1G>A, leads to intolerance to fluoropyrimidines. Due to the low frequency of this variant in many populations, the prevalence of fluoropyrimidine-induced hematologic side effects in CRC patients with the c.1905 + 1G>A variant is unclear. In this study, we investigated the prevalence of the DPYD c.1905 + 1 variants in a Turkish CRC cohort and the potential effects of these variants on fluoropyrimidine-induced hematologic side effects.